Title: New parenteral anticoagulants: focus on factor Xa and thrombin inhibitors.
Journal: Current drug discovery technologies 20120601
Title: Emerging anticoagulants.
Journal: Current medicinal chemistry 20120101
Title: Inhibitors of propagation of coagulation: factors V and X.
Journal: British journal of clinical pharmacology 20111001
Title: New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.
Journal: Pharmacotherapy 20111001
Title: Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease?
Journal: Reviews on recent clinical trials 20110501
Title: Future anticoagulants in interventional cardiology: anti-IXa and anti-Xa agents in percutaneous coronary intervention.
Journal: Future cardiology 20110501
Title: Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.
Journal: Expert opinion on investigational drugs 20110401
Title: New parenteral anticoagulants in development.
Journal: Therapeutic advances in cardiovascular disease 20110201
Title: New anticoagulant agents in acute coronary syndromes.
Journal: Heart (British Cardiac Society) 20110201
Title: A network-based multi-target computational estimation scheme for anticoagulant activities of compounds.
Journal: PloS one 20110101
Title: Emerging therapies for acute coronary syndromes.
Journal: Frontiers in pharmacology 20110101
Title: Clinical pharmacology of direct and indirect factor Xa inhibitors.
Journal: Drugs 20101112
Title: Factor Xa inhibitors: next-generation antithrombotic agents.
Journal: Journal of medicinal chemistry 20100909
Title: What goes into a major acute coronary syndrome trial and what will future trials look like?
Journal: Current cardiology reports 20100701
Title: Recent research on antithrombotics. News on the treatment of patients with acute coronary syndromes.
Journal: Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 20100501
Title: New drugs for the treatment of coronary artery syndromes: otamixaban and ticagrelor.
Journal: Expert opinion on pharmacotherapy 20100201
Title: Post-operative thromboprophylaxis: new oral thrombin and factor X inhibitors and their place in clinical practice.
Journal: F1000 medicine reports 20100101
Title: Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.
Journal: Lancet (London, England) 20090905
Title: Otamixaban in acute coronary syndromes.
Journal: Lancet (London, England) 20090905
Title: [What's new on antithrombotics?].
Journal: Annales de cardiologie et d'angeiologie 20090801
Title: [Factor Xa-inhibition in interventional cardiology].
Journal: Hamostaseologie 20071201
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20070901
Title: Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.
Journal: Circulation 20070522
Title: The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.
Journal: Current medicinal chemistry 20070101
Title: Drug evaluation: the directly activated Factor Xa inhibitor otamixaban.
Journal: IDrugs : the investigational drugs journal 20061201
Title: Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
Journal: Clinical pharmacology and therapeutics 20061201
Title: Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.
Journal: Expert opinion on investigational drugs 20060801
Title: Asymmetric synthesis of intermediates for otamixaban and premafloxacin by the chiral ligand-controlled asymmetric conjugate addition of a lithium amide.
Journal: The Journal of organic chemistry 20060609
Title: Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid.
Journal: Thrombosis and haemostasis 20060201
Title: Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure.
Journal: Journal of clinical pharmacology 20060101
Title: Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects.
Journal: Journal of clinical pharmacology 20060101
Title: Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.
Journal: Thrombosis and haemostasis 20051201
Title: Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers.
Journal: Thrombosis and haemostasis 20050401
Title: Small molecule coagulation cascade inhibitors in the clinic.
Journal: Current topics in medicinal chemistry 20050101
Title: Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.
Journal: Bioorganic & medicinal chemistry letters 20020617
Title: Pharmacological characterization of a novel factor Xa inhibitor, FXV673.
Journal: Thrombosis research 20010815
Title: Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs.
Journal: Journal of cardiovascular pharmacology 20010801
Title: Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
Journal: British journal of pharmacology 20010801
Title: Eikelboom JW, Weitz JI.Otamixaban in acute coronary syndromes.Lancet. 2009 Sep 5;374(9692):762-4. Epub 2009 Aug 28.
Title: Sabatine MS, Antman EM, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.Lancet. 2009 Sep 5;374(9692):787-95. Epub 2009 Aug 28
Title: Guertin KR, Choi YM.The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.Curr Med Chem. 2007;14(23):2471-81.
Title: Cohen M, Bhatt DL, et al. SEPIA-PCI Trial Investigators.Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.Circulation. 2007
Title: Guertin, Kevin R.; Choi, Yong-Mi.The discovery of the factor Xa inhibitor Otamixaban: from lead identification to clinical development.Current Medicinal Chemistry (2007), 14(23), 2471-2481.
